Rising adoption of antinuclear antibody tests owing to increasing prevalence of autoimmune diseases is a major factor supporting market revenue growth.
Rising adoption of antinuclear antibody tests owing to increasing prevalence of autoimmune diseases is a major factor supporting market revenue growth
The global antinuclear antibody test market size is expected to reach USD 3.44 billion in 2028 and register a CAGR of 12.8% over the forecast period, according to the latest report by Reports and Data. Increasing prevalence of autoimmune disorders, rising healthcare awareness, and rapidly increasing global geriatric population are some key factors driving global market revenue growth.
Antinuclear Antibodies (ANA) are autoantibodies produced by a person’s immune system as it is unable to distinguish between its healthy cells and foreign particles. They directly bind to nucleus of the cell and are often called antinuclear. Antinuclear antibody test is primarily performed to detect the presence of autoantibodies in the blood and aids in diagnosis of autoimmune diseases such as rheumatoid arthritis, Sjogren’s syndrome, and Systemic Lupus Erythematosus (SLE). Significant factors such as rising investment in R&D for developing advanced products, growing healthcare expenditure in many countries, and favorable reimbursement policies and schemes and health insurance coverage are fueling growth of the global antinuclear antibody test market.
However, stringent regulations imposed on approval of specific medical devices, high cost of equipment, and lack of trained personnel to handle certain advanced devices are some factors expected to hamper global market growth to some extent.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/4080
Some key highlights from the report:
- Among the product segments, the reagents and assay kits segment is projected to account for substantial revenue share over the forecast period. Rising prevalence of autoimmune disorders, increasing demand for ANA tests, and high adoption of reagents and assay kits in hospitals and clinical settings are some major factors driving revenue growth of this segment.
- Based on technique, the ELISA segment is projected to register fastest revenue growth between 2021 and 2028. Increasing adoption of ELISA technique in hospitals and clinics is due to favorable features such as easy automation, high specificity, and no requirement of trained skilled professionals.
- On the basis of technique, the rheumatoid arthritis segment is expected to account for substantial revenue growth throughout the forecast period. Increasing prevalence of rheumatoid arthritis across the globe and increasing global geriatric population are major factors fueling revenue growth of this segment.
- Among the end use segments, the clinical laboratories segment is expected to register fastest revenue growth during the forecast period. Rapid revenue growth is due to increasing investments in clinical research, rising prevalence of autoimmune diseases, and ongoing research and tests for diagnosis of various types of autoimmune diseases.
- Europe is projected to account for substantial revenue growth over the forecast period owing to rising prevalence of autoimmune diseases, increasing healthcare spending, and adoption of latest technology for testing. In addition, better healthcare insurance policies and government initiatives for covering healthcare expenses are further fueling market growth in this region.
- Asia Pacific is expected to register fastest revenue CAGR of 12.2% throughout the forecast period. This can be attributable to increasing prevalence of autoimmune diseases such as SLE and rheumatoid arthritis, increasing public awareness, improving healthcare systems and rising government funding for research and development activities.
- Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.) are some major players in the global antinuclear antibody test market.
Buy now your Exclusive copy of Report @ https://www.reportsanddata.com/checkout-form/4080
For this study, Reports and Data has segmented the global antinuclear antibody test market based on product, technique, application, end use, and region:
Product Outlook (Revenue, USD Billion, 2018-2028)
- Reagents & Assay Kits
- Systems
- Software & Services
Technique Outlook (Revenue, USD Billion, 2018-2028)
- ELISA
- Immunofluorescence Assay
- Multiplex Assay
Application Outlook (Revenue, USD Billion, 2018-2028)
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjogren’s Syndrome
- Scleroderma
- Others
End-use Outlook (Revenue, USD Billion, 2018-2028)
- Hospitals
- Clinical Laboratories
- Physician Office Laboratories
- Others
Request for Custom Research @ https://www.reportsanddata.com/request-customization-form/4080
Regional Outlook (Revenue, USD Million, 2018 - 2028)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Rest Of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of MEA
Explore Reports and Data’s Prime Analysis of the global Pharmaceutical & Healthcare Industry:
Antibody Production Market By Class (Monoclonal antibodies, Murine, Chimeric, Humanized, Polyclonal Antibodies), End User (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Research Institutes), By Process And Segment Forecasts, 2016-2026
Rabies Monoclonal Antibody Market Size, Share & Analysis, By Product Type (Category II Exposure, Category III Exposure), By Application (Adult, Children), And By Region, Forecast To 2028
Blood Group Typing Market Size, Share & Analysis, By Product & Service (Consumables, Instrument, Services), By Technique (PCR-based and Microarray, Assay-based, Massively Parallel Sequencing, Others), By Test Type (Antibody Screening, HLA Typing, Cross-matching, ABO Blood Tests, Antigen Typing), By End-Use (Hospitals, Blood Banks, Clinical Laboratories, Others), And By Region, Forecast To 2028
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Read Full Press Release: https://www.reportsanddata.com/press-release/global-antinuclear-antibody-test-market